March newsletter 2022

16/03/2022

News /
March newsletter 2022

Please view the full newsletter here.

Pembroke VCT is now a £180 million fund with a maturing portfolio of over 40 growth-stage companies. In the 12 months to December 2021, we are proud to have increased our total return from 127.2p to 148.3p per share, as well increased our NAV by +10.1p to 123.3p per share. We are also excited to be backing the next chapter of growth for exceptional entrepreneurs in our portfolio, continuing with our stepping-stone investment philosophy, completing 17 follow-on investments (totalling £20 million) and 7 new company investments (totalling £8.7 million).

Having launched our offer in September 2021, we have raised £35 million (as of 16 March 2022) out of our £60 million target, with just under one month to go before the end of the tax year.

In this issue, we would like to tell you about our new £3 million investment into the fascinating surgical software company Cydar Medical, in addition to welcoming TALA and Annie Mals to the portfolio.

06/03/2023

Pembroke VCT’s Latest News

View the full newsletter here. As we reflect on 2022, it is clear to us that it has not been all doom and gloom. As in previous times of economic uncertainty, ambitious founders and management teams grasp opportunities that ensure their businesses not only survive, but in many cases, thrive. We are proud to partner […]

09/02/2023

Branding Workshop with Sonder & Tell

How do you build a compelling brand story that customers will resonate with? We recently hosted an Branding Workshop for our founders in partnership with Kate Hamilton and Lucinda Toole from Brand Strategy agency, Sonder & Tell to find out what makes a good story and how companies should apply this framework to create an […]

06/02/2023

Dividend Declaration & Net Asset Value

Dividend The Board of Pembroke VCT plc has resolved to pay an interim dividend of 2.5 pence per B Ordinary Share on 30 May 2023. The record date for the interim dividend is 28 April 2023, the ex-dividend date is 27 April 2023 and the last date for receipt of elections in respect of the […]

16/11/2022

Half-yearly report for the six months ended 30 September 2022

The Directors are pleased to attach the Company’s Half-Year report for the six months ended 30 September 2022. Click on, or paste the following link into your web browser, to view the associated PDF document. https://pembrokevct.com/wp-content/uploads/2022/11/Pembroke-HYR-2022.pdf For further information, please contact: Andrew Wolfson / Chris Lewis Pembroke Investment Managers LLP (Manager) +44 20 7766 6900 […]

07/11/2022

Pembroke VCT invests £1.5m into accessible womenswear brand Ro&Zo

Pembroke VCT has today invested £1.5 million into accessible womenswear brand Ro&Zo to drive its direct to consumer offering and expand the business. The deal was managed by strategic advisory firm finnCap. Ro&Zo is a female-founded brand made by women, for women. Established by co-founders Rosie Bowden and Zoe de Abreu in the aftermath of […]

01/11/2022

Pembroke VCT invests £1 million into aspirational makeup brand, VIEVE

Pembroke VCT has today invested £1 million into VIEVE, the aspirational and purposeful makeup brand transforming the cosmetic landscape, as part of a £5.5 million Series A round. Investing alongside Pembroke VCT are Venrex and Samos (the early stage investors in Charlotte Tilbury) and Active Partners. Born from artistic passion and purposeful belief in the […]

26/09/2022

Pembroke VCT leads £3.7m investment into ethical glasses brand Bloobloom

Pembroke VCT has invested £2.5 million into ethical glasses company Bloobloom as part of a £3.7 million fundraise. Investing alongside Pembroke VCT are DMG Ventures and several angel investors. Established in 2018 by brothers Abbas and Fares Manai, Bloobloom is disrupting the glasses market by selling premium spectacles and sunglasses at a fair price, via […]

08/09/2022

Publication of Prospectus

View the full prospectus here. Pembroke VCT plc (the “Company”) has today published a prospectus (the “Prospectus”) in relation to the offer for subscription of up to £40 million of B Ordinary Shares of 1p each in the capital of the Company with an over-allotment facility for up to a further £20 million of B […]